Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009

DOI to cite this document:: 10.5283/epub.805

Schlingensiepen, Karl-Hermann ; Schlingensiepen, Reimar ; Steinbrecher, Andreas ; Hau, Peter ; Bogdahn, Ulrich ; Fischer-Blass, Birgit ; Jachimczak, Piotr

PDF
(903kB) - Repository staff only

Date of publication of this fulltext: 05 Aug 2009 13:24

Alternative links to fulltext:DOI Pubmed Publisher

Details

Export bibliographical data

Abstract

TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense ...